Stock Analysis
- Taiwan
- /
- Medical Equipment
- /
- TWSE:4106
Wellell First Quarter 2024 Earnings: EPS: NT$0.40 (vs NT$0.50 in 1Q 2023)
Wellell (TWSE:4106) First Quarter 2024 Results
Key Financial Results
- Revenue: NT$646.7m (down 7.6% from 1Q 2023).
- Net income: NT$40.0m (down 21% from 1Q 2023).
- Profit margin: 6.2% (down from 7.2% in 1Q 2023). The decrease in margin was driven by lower revenue.
- EPS: NT$0.40 (down from NT$0.50 in 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Wellell's share price is broadly unchanged from a week ago.
Risk Analysis
Don't forget that there may still be risks. For instance, we've identified 2 warning signs for Wellell that you should be aware of.
Valuation is complex, but we're helping make it simple.
Find out whether Wellell is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TWSE:4106
Wellell
Provides medical solutions for healthcare professionals worldwide.
Flawless balance sheet, good value and pays a dividend.